Tumorad(R) Shows Good Safety in Preclinical Studies
LUND, SWEDEN / ACCESSWIRE / December 6, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) today announced it has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad (SN201). It displays a good safety margin to clinically relevant doses.
"The completion of the regulatory preclinical studies is an important step towards the clinical development phase. The preparations for the first study with SN201 in humans are proceeding according to plan and we expect to be ready to start phase I/II in next year ", said CEO Mats Hansen.
The preclinical package included toxicology- and dosimetry-studies in rat. The results showed that the nanomaterial is safe to give in doses that widely exceed planned clinical doses, and that radiation is distributed in the body in a manner that allow dosing according to plan.
"The results confirm the data we previously have seen in pilot studies and mean that we with confidence can proceed with SN201 to the clinic. This is a major risk reduction in the project ", said Oskar Axelsson, CSO at Spago Nanomedical.
Data from the preclinical studies, together with other documentation, will form the basis for the first clinical trial application with Tumorad. The plan is to submit the application and start the studies in humans in 2022. The aim for the clinical study is to document safety at different doses of Tumorad in cancer patients as well as to evaluate signs of early proof-of-concept.
The preclinical regulatory program, conducted in collaboration with Charles River Laboratories and Minerva Imaging, included both toxicity and dosimetry studies.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, firstname.lastname@example.org
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, email@example.com .
This information is information that Spago Nanomedical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-06 08:00 CET.
SOURCE: Spago Nanomedical
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Cyberlux Corporation21.1.2022 17:32:37 CET | Press release
Cyberlux Corporation Announces Mr. Chris Damvakaris as Chief Revenue Officer to Lead the Revenue Growth Plans and Strategic Partnerships for the Advanced Digital Technology Company
Episode Six18.1.2022 15:04:37 CET | Press release
Third Anniversary of Episode Six and HSBC's Partnership Shows the Power of Banks and Fintechs Working Together
XPhyto Therapeutics Corp. 17.1.2022 09:06:46 CET | Press release
XPhyto Announces Head of Sales, Europe
Loop Industries, Inc.16.1.2022 22:01:39 CET | Press release
Loop Industries Announces Selection of Port-Jérôme, in Normandy, France, as Site for First European Infinite Loop Manufacturing Facility
XPhyto Therapeutics Corp13.1.2022 09:07:06 CET | Press release
XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia
XPhyto Therapeutics Corp. 10.1.2022 09:06:52 CET | Press release
XPhyto Announces New Director of Business Development and Head of Diagnostic Research
Re:NewCell AB (publ)5.1.2022 11:51:32 CET | Press release
Successful Industrial Scale Viscose Filament Yarn Production from 100 Percent Circulose(R)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom